Coherus Biosciences (NASDAQ:CHRS) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

CHRS has been the topic of several other research reports. Zacks Investment Research lowered Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. Credit Suisse Group restated an “outperform” rating and issued a $17.00 price objective (down previously from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. ValuEngine lowered Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, Citigroup restated a “buy” rating and issued a $23.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $29.67.

Shares of Coherus Biosciences (NASDAQ CHRS) opened at $13.60 on Friday. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $28.60. The stock has a market capitalization of $788.06, a PE ratio of -2.51 and a beta of 3.89. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84.

Coherus Biosciences (NASDAQ:CHRS) last released its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. analysts expect that Coherus Biosciences will post -4.39 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of Coherus Biosciences by 32.7% in the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,785 shares during the last quarter. Legal & General Group Plc grew its position in shares of Coherus Biosciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,046 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Coherus Biosciences by 497.4% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 10,491 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Coherus Biosciences in the second quarter valued at approximately $185,000. Finally, Voya Investment Management LLC grew its position in shares of Coherus Biosciences by 32.2% in the second quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 4,293 shares during the last quarter. 81.00% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Coherus Biosciences (CHRS) Upgraded by BidaskClub to “Buy”” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://theolympiareport.com/2018/01/13/coherus-biosciences-chrs-upgraded-by-bidaskclub-to-buy.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.